Pharmaceutical

Anticipation rises for RSV rollout as positive data emerges

Following major successes in the RSV landscape over the last few years, experts debate rollout plans.

Feb 24, 2024 - 18:00
Following major successes in the RSV landscape over the last few years, experts debate rollout plans.
Read the original article

Tags:

Previous Article

FDA to decide on Sanofi/Regeneron’s Dupixent for COPD in June

Next Article

Bavarian Nordic’s chikungunya vaccine secures EMA fast-track

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

RVAC and University of Pennsylvania to develop mRNA vaccines

RVAC and University of Pennsylvania to develop mRNA vac...

Mar 21, 2023

STAT+: Early findings in gene therapy death suggest CRISPR was not the cause

STAT+: Early findings in gene therapy death suggest CRI...

Apr 27, 2023

Johnson & Johnson bets heavy on AI-driven drug discovery

Johnson & Johnson bets heavy on AI-driven drug discovery

Dec 1, 2023